C. diff Risk


Oral Bioavailability


Approximate Cost


Spectrum Of Activity


1g IV q24h

0 - 29 eGFR30+ eGFR500mg IV q24h1g IV q24h

500mg IV daily, dose after dialysis on HD days

General Information

Common Usage

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

Adverse Effects

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems


Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4.0

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Moderate